HERDOO2 Rule for Discontinuing Anticoagulation in Unprovoked VTE
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low Risk0–1
- Not Low Risk2–4
The HERDOO2 Rule for Discontinuing Anticoagulation in Unprovoked VTE calculates determining thromboembolic risk, heparin-induced thrombocytopenia probability, and bleeding diathesis. Key inputs include post thrombotic signs. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Identifies low-risk women who can safely discontinue anticoagulation after completing treatment for unprovoked venous thromboembolism (VTE). The rule helps clinicians decide which patients can stop anticoagulation therapy after the initial treatment period.
Clinical Indication
The HERDOO2 Rule for Discontinuing Anticoagulation in Unprovoked VTE is indicated for bedside clinical practice to support Identifies low-risk women who can safely discontinue anticoagulation after completing treatment for unprovoked venous thromboembolism (VTE). The rule helps clinicians decide which patients can stop anticoagulation therapy after the initial treatment period.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.
Limitations & Contraindications
Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention. Clinical exclusion: Not applicable to men or women with provoked VTE.
Clinical Pearls & Action Plan
Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies.
Score = Post-thrombotic signs (1 point) + D-dimer ≥250 μg/L (1 point) + BMI ≥30 kg/m² (1 point) + Age ≥65 years (1 point)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| post_thrombotic_signs | string | Yes | Hyperpigmentation, edema, or redness in either leg |
| d_dimer_level | string | Yes | D-dimer level measured while on anticoagulation |
| bmi | string | Yes | Body Mass Index |
| age | string | Yes | Patient age |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–1 | Low Risk | Can discontinue anticoagulation |
| 2–4 | Not Low Risk | Continue anticoagulation |
Evidence-Based References (EBM)
- Rodger MA, Kahn SR, Wells PS, Anderson DA, Chagnon I, Le Gal G, et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ. 2008 Aug 26;179(5):417-26.
- Rodger MA, Le Gal G, Anderson DR, Schmidt J, Pernod G, Kahn SR, et al.; REVERSE II Study Investigators. Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study. BMJ. 2017 Mar 17;356:j1065.